A new phase II trial finds that PET scans obtained before and midway through treatment for p16-positive oropharynx cancer (OPC) can help determine whether a patient can receive a lower dose of radiation therapy in the second half of their treatment course without compromising cancer control.
Lindsay Kobayashi, Ph.D., an assistant professor in the University of Michigan School of Public, Health.is helping Rogel researchers answer big questions about cancer and aging.
Zeribe Nwosu, Ph.D., a postdoctoral trainee in the labs of Costas Lyssiotis, Ph.D., and Marina Pasca Di Magliano, Ph.D., is focused on the intersection of metabolism, genomics and the immune system in pancreatic cancer.
Dr. Lori Pierce shares her views now the institutional racism is finally being recognized on race and societal plague that is devastating to all of us — and as physicians
and researchers, we must do more to confront the longstanding inequities that pervade oncology and all of medicine.
Dr. Aki Morikawa discusses Rogel’s IMPACT program -- Improve Metastatic Breast Cancer Patient Access to Coordinated Treatment. This is a collaboration of medical, surgical and radiation oncologists, and specialists in genetic testing and counseling, physical rehabilitation, neuropsychology and palliative care. It is single point of care coordination for patients with advanced disease.
Max Wicha, M.D., founding director of the Rogel Cancer Center, reflects on the progress of cancer treatment and research on the 50th anniversary of the National Cancer Act. From his perspective, this act changed the way doctors treated cancer and encouraged them to share information with researchers. By combining their efforts, better and more effective treatments were developed.
MENU
